Dublin, May 21, 2025 (GLOBE NEWSWIRE) -- The "Measles, Mumps, Rubella Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" has been added to ResearchAndMarkets.com's offering.
The Measles, Mumps, Rubella Vaccine Market was valued at USD 1.87 Billion in 2024 and is projected to reach USD 3.04 Billion by 2030, rising at a CAGR of 8.42%. Market growth is being fueled by increasing demand for immunization as a fundamental public health measure.
The inclusion of MMR vaccines in national immunization schedules, bolstered by support from international agencies such as WHO and UNICEF, has led to widespread adoption in both high- and low-income countries. Recurring outbreaks of measles, especially in underserved populations, highlight the need for large-scale vaccination campaigns. Strengthening healthcare infrastructure, public-private partnerships, and improved distribution logistics are further enhancing vaccine access and coverage.
Innovation in vaccine delivery methods, including thermostable and needle-free formulations, is also driving growth, particularly in resource-constrained settings. The trend of combining MMR with other pediatric vaccines into a single-dose format is simplifying immunization schedules and improving adherence. Integration with digital health systems is aiding in tracking vaccination coverage and follow-ups, enhancing program efficiency.
Key Market Driver: Increasing Government Immunization Initiatives
Government-led immunization initiatives have become a pivotal factor driving the global MMR vaccine market. Countries worldwide are prioritizing vaccine-preventable disease control by integrating MMR into routine childhood immunization programs, often at no cost. Increased funding, improved logistics, and targeted rural outreach are elevating vaccine coverage. Supported by organizations such as WHO, UNICEF, and Gavi, these initiatives are reducing disease incidence and mortality, particularly in low-income nations.
Despite such efforts, global immunization coverage still falls short of WHO's 95% target needed for measles elimination. In 2023, only 83% of children globally received the first measles vaccine dose, while just 74% received the second. Alarmingly, over 22 million children missed their first dose. These figures underline the urgency for governments to scale up immunization efforts through enhanced policies, monitoring, and education, reinforcing sustained demand for MMR vaccines.
Key Market Challenge: Vaccine Hesitancy and Misinformation
Vaccine hesitancy, driven by misinformation and distrust, remains a substantial barrier to broader adoption of MMR vaccines. Persistent myths, such as a link between the MMR vaccine and autism, continue to undermine public confidence despite being scientifically disproven. The proliferation of false information via social media and other platforms exacerbates hesitancy, particularly in communities with limited access to reliable healthcare education.
These attitudes delay or reduce vaccine uptake, leading to disease resurgence and undermining public health goals. Overcoming this issue requires coordinated efforts involving community leaders, healthcare providers, and policymakers to promote accurate information and build trust. Tailored education campaigns and transparent communication strategies will be key to addressing misinformation and improving vaccine acceptance across regions.
Key Market Trend: Integration of MMR Vaccines into Universal Immunization Programs
The increasing integration of MMR vaccines into universal immunization programs is a notable trend supporting market expansion. Governments, with backing from global health bodies, are embedding MMR vaccination within broader public health strategies to improve childhood immunization coverage. These efforts are essential in achieving herd immunity and controlling disease outbreaks.
According to WHO, global measles vaccine coverage remains insufficient, with only 83% of children receiving the first dose and 74% the second in 2023. Nearly 35 million children lacked full protection against measles. These gaps emphasize the need for inclusive immunization strategies. As countries intensify efforts to close these coverage gaps, the demand for reliable MMR vaccines is expected to grow significantly.
Key Players Profiled in this Measles, Mumps, Rubella Vaccine Market Report
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Pfizer Inc.
- Novartis AG
- Serum Institute of India Pvt. Ltd.
- Panacea Biotec Ltd.
- Takeda Pharmaceutical Company Limited
- Sinovac Biotech Ltd.
- Biological E. Limited
- Emergent BioSolutions Inc.
Report Scope
In this report, the Global Measles, Mumps, Rubella Vaccine Market has been segmented into the following categories:
Measles, Mumps, Rubella Vaccine Market, by Type:
- Monovalent
- Trivalent (combined MMR)
- Tetravalent
Measles, Mumps, Rubella Vaccine Market, by Targeted Population:
- Infants and Children (9 months to 12 years)
- Adults
Measles, Mumps, Rubella Vaccine Market, by Distribution Channel:
- Hospitals and Healthcare Institutions
- Vaccine Centers and Public Health Clinics
- Pediatric and Private Healthcare Clinics
Measles, Mumps, Rubella Vaccine Market, by Region:
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Key Attributes
| Report Attribute | Details |
| No. of Pages | 183 |
| Forecast Period | 2024-2030 |
| Estimated Market Value (USD) in 2024 | $1.87 Billion |
| Forecasted Market Value (USD) by 2030 | $3.04 Billion |
| Compound Annual Growth Rate | 8.4% |
| Regions Covered | Global |
For more information about this report visit https://www.researchandmarkets.com/r/pz18uj
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
